RecruitingNCT06852807

18F-mFBG PET Imaging in the Evaluation of Neuroblastoma

Prospective Clinical Study of 18F-mFBG PET Imaging in Neuroblastoma


Sponsor

First Affiliated Hospital of Zhejiang University

Enrollment

200 participants

Start Date

Feb 4, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.


Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new PET scan tracer to see how well it detects and monitors neuroblastoma, a type of cancer that mostly affects young children and starts in nerve tissue. **You may be eligible if:** - You are between 0 and 18 years old - You have been clinically suspected of having neuroblastoma or have already been diagnosed - A parent or legal guardian is available to provide consent **You may NOT be eligible if:** - You have serious disease affecting the heart, brain, liver, kidneys, or blood-forming system - You have had significant radiation exposure from other medical studies in the past year - You have received an experimental drug or device within the past month - You have any condition the investigator believes would make participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG18F-MFBG

Patients with neuroblastoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.


Locations(1)

The First Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06852807


Related Trials